{"id":"NCT03216226","sponsor":"Zealand Pharma","briefTitle":"A Trial to Evaluate the Immunogenicity of Dasiglucagon and GlucaGen in Patients With Type 1 Diabetes Mellitus","officialTitle":"A Phase 3, Randomized, Double-Blind, Parallel Group Safety Trial to Evaluate the Immunogenicity of Dasiglucagon and GlucaGenÂ® Administered Subcutaneously in Patients With Type 1 Diabetes Mellitus (T1DM)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-06-28","primaryCompletion":"2018-02-13","completion":"2018-02-13","firstPosted":"2017-07-13","resultsPosted":"2021-02-16","lastUpdate":"2021-05-04"},"enrollment":112,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Hypoglycemia","Diabetes Mellitus, Type 1"],"interventions":[{"type":"DRUG","name":"dasiglucagon","otherNames":["ZP4207"]},{"type":"DRUG","name":"GlucaGen","otherNames":["GlucaGen HypoKit"]}],"arms":[{"label":"dasiglucagon (ZP4207)","type":"EXPERIMENTAL"},{"label":"GlucaGen","type":"EXPERIMENTAL"}],"summary":"The trial's objective is to evaluate the immunogenicity of repeated single doses of dasiglucagon\\* and GlucaGen following subcutaneous (SC) administration in patients with type 1 diabetes mellitus (T1DM) and further to evaluate the safety and tolerability of dasiglucagon and GlucaGen.\n\n\\*dasiglucagon is the proposed International Nonproprietary Name (pINN) for ZP4207","primaryOutcome":{"measure":"Percentage of Patients With ADA","timeFrame":"104 days after the first dose","effectByArm":[{"arm":"Dasiglucagon (ZP4207)","deltaMin":0,"sd":null},{"arm":"GlucaGen","deltaMin":0,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":19},"locations":{"siteCount":7,"countries":["United States","Austria","Canada","Germany"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":57},"commonTop":["Hypoglycemia","Nausea","Vomiting","Viral upper respiratory tract infection","Headache"]}}